Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
09/2003
09/25/2003WO2003077924A1 Continuous sulfatase inhibiting progestogen hormone replacement therapy
09/25/2003WO2003077919A1 Fluorinated 4-azasteroid derivatives as androgen receptor modulators
09/25/2003WO2003077916A1 Use of proton pump inhibitors for the treatment of noncardiac chest pain
09/25/2003WO2003077912A1 Method of treatment and/or prophylaxis
09/25/2003WO2003077907A1 Azetidine derivatives as ccr-3 receptor antagonists
09/25/2003WO2003077901A1 Preventing and/or treating cardiovascular disease and/or associated heart failure
09/25/2003WO2003077898A1 Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
09/25/2003WO2003077897A1 Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
09/25/2003WO2003077893A2 Compositions for treating digestive functional pathologies
09/25/2003WO2003077892A2 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for treating ang ii-mediated diseases
09/25/2003WO2003077884A1 A topical synergistic microbicide
09/25/2003WO2003077881A2 Method for production of phytoalexins
09/25/2003WO2003077861A2 Water-based delivery systems
09/25/2003WO2003077857A2 N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
09/25/2003WO2003077850A2 N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
09/25/2003WO2003077841A2 Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases
09/25/2003WO2003068171A3 Method and composition for treatment of inflammation and aids-associated neurological disorders
09/25/2003WO2003068159A3 Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
09/25/2003WO2003061594A3 Methods and compositions for reducing the development of drug tolerance and/or physical dependence
09/25/2003WO2003059277A3 Methods and compositions for stimulating bone growth using inhibitors of microtubule assembly
09/25/2003WO2003045434A3 Endothelin antagonists ina method and composition for potentiating an opiate analgesic
09/25/2003WO2003042411A3 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease
09/25/2003WO2003040295A3 Ion channel
09/25/2003WO2003020219A3 Aerosolized decongestants for the treatment of sinusitis
09/25/2003WO2003015690A3 Method for treating primary insomnia
09/25/2003WO2003013577A3 Use of il-18 inhibitors in hypersensitivity disorders
09/25/2003WO2003013537A3 Irinotecan for treatment of cancer
09/25/2003WO2003013535A3 Use of irinotecan for improved treatment of cancer based on mdr1
09/25/2003WO2003011855A3 Pyrazole-derived kinase inhibitors and uses thereof
09/25/2003WO2003007924A3 Combinations comprising epothilones and pharmaceutical uses thereof
09/25/2003WO2003002114A3 Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
09/25/2003WO2003002108A3 Use of tyrosine kinase inhibitors for treating inflammatory diseases
09/25/2003WO2003001968A3 Compositions and methods for inhibiting platelet activation and thrombosis
09/25/2003WO2002102981A3 SIR2α-BASED THERAPEUTIC AND PROPHYLACTIC METHODS
09/25/2003WO2002100827A9 Method for increasing the survival of dopamine secreting cells
09/25/2003WO2002096357A3 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
09/25/2003WO2002077263A3 Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
09/25/2003WO2002076482A3 USE OF IKK-β INHIBITORS AND METHOD FOR DISCOVERY OF SAID INHIBITORS
09/25/2003WO2002069995A3 Use of trail and antiprogestins for treating cancer
09/25/2003WO2002064612A9 Human g-protein chemokine receptor (ccr5) hdgnr10
09/25/2003WO2002063004A3 G-protein coupled receptors
09/25/2003WO2002055688A8 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
09/25/2003WO2002046419A3 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
09/25/2003WO2002031146A3 Isolated human nuclear hormone receptors, nucleic acid molecules encoding human nuclear hormone receptors, and uses thereof
09/25/2003WO2002028432A3 Stem cell-based methods for preventing and treating tumor
09/25/2003WO2002028355A3 Methods and compositions for enhancing angiogenesis
09/25/2003WO2002026982A3 Secreted human proteins
09/25/2003WO2002024910A3 Isolated human transporter proteins, nucleic acid molecules encoding them, and uses thereof
09/25/2003WO2002020846A3 Screening methods to identify compounds that modulate a response of a cell to ultraviolet radiation exposure
09/25/2003WO2002017855A3 Process for preparing pharmaceutical compositions for use with soft gelatin formulations
09/25/2003WO2002017789A3 Methods and devices for quantitative analysis of x-ray images
09/25/2003WO2002014489A9 Leucine-rich repeat-containing g-protein coupled receptor-8 molecules and uses thereof
09/25/2003WO2002013833A3 SMALL MOLECULE INHIBITORS TARGETED AT Bcl-2
09/25/2003US20030182668 Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors
09/25/2003US20030182667 Type iii allergic inflammation model animal
09/25/2003US20030181847 For topical treatment of nail diseases (onychomycosis) after forming aperture in infected nail with laser beam; fungicides (terbinafine)
09/25/2003US20030181728 Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
09/25/2003US20030181714 Oligosaccharide chain, which contianing a terminal NeuNAc alpha 6 linked to a linear or branched polylcatosamine type structure containing at least 3 lactosamine; a linear or branched structure with two lactosamine and one lactose
09/25/2003US20030181689 Percarboxylated polysaccharides, and a process for their preparation
09/25/2003US20030181658 Exhibit protease activity as a single chain or as an activated two chain form; use of polypeptides to identify compounds that modulate the protease activity thereof and as tumor markers
09/25/2003US20030181529 Method for preventing and treating peripheral neuropathy by administering selegiline
09/25/2003US20030181518 Compositions and methods for treating cystic fibrosis
09/25/2003US20030181512 For therapy and prophylaxis of obesity and hyperlipidemia; side effect reduction
09/25/2003US20030181508 For therapy of attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder
09/25/2003US20030181500 For therapy and prophylaxis of cardiac failure, the prevention of ischemic coronary heart disease or recurrence of ischemic coronary heart disease
09/25/2003US20030181497 Heterocyclic acridone inhibitors of IMPDH enzyme
09/25/2003US20030181495 Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
09/25/2003US20030181491 C2-disubstituted indan-1-ol compounds, their derivatives, processes for their preparation, and their use as pharmaceuticals
09/25/2003US20030181490 For therapy and prophylaxis of acquired immune deficiency syndrome (AIDS), or ARC
09/25/2003US20030181486 Novel use of(r) -(-) -2-[5-(4-fluorophenyl)-3- pyridylmethylaminomethy]-chromane and its physiologically acceptable salts )
09/25/2003US20030181478 A liquid, propellant-free mixtures for treating asthma or chronic obstructive pulmonary disease; tiotropium bromide
09/25/2003US20030181463 Antiviral azaindole derivatives
09/25/2003US20030181461 Use of phosphodiesterase antagonists to treat insulin resistance
09/25/2003US20030181452 Inotropic agents such as (S)-N-tert-butyloxycarbonyl-N-methyl-tyrosyl)-4-(4-nitrophenyl)-piperazine, used for preventing and/or prophylaxis of diseases associated with adenosine 5'-triphosphate
09/25/2003US20030181435 Systemic lupus erythematosus therapy
09/25/2003US20030181426 Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
09/25/2003US20030181422 Cardioprotective phosphonates and malonates
09/25/2003US20030181418 Pharmaceutical composition
09/25/2003US20030181411 Contacting and adsorbing an insoluble enzyme inhibitor with a surface stabilizer
09/25/2003US20030181398 Injecting penicillins, cephalosporins, tetracyclines, erythromycins, tylosins, quinolone and other antibiotics, to skins of animals such as cattle, swine or sheep, for prophylaxis of respiratory system disorders
09/25/2003US20030181379 Novel fibroblast growth factor (FGF23) and methods for use
09/25/2003US20030181374 Methods and compositions for stimulating bone growth using inhibitors of microtubule assembly
09/25/2003US20030181371 Compositions and methods of using collajolie
09/25/2003US20030181364 Genes and methods for the screening of therapeutics useful for treating impaired glucose tolerance conditions, as well as diagnostics and therapeutic compositions for identifying or treating such conditions.
09/25/2003US20030181363 Compounds or pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.
09/25/2003US20030181356 Treating emphysema by reducing the amount of force the fibers in the lung (e.g., the collagen and elastin fibers in the walls of the alveoli) must bear. The invention features a pharmaceutically acceptable composition comprising lipid for
09/25/2003US20030181353 Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia
09/25/2003US20030180953 Gene disruption methodologies for drug target discovery
09/25/2003US20030180934 Plasminogen-like polynucleotides, polypeptides, and antibodies
09/25/2003US20030180931 Cellubrevin homologs
09/25/2003US20030180893 Biotransformation of biologically active compounds made of various classes of chemical substance by means of laccase and manganese peroxidase enzymes
09/25/2003US20030180887 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
09/25/2003US20030180877 Gene therapy; drug screening
09/25/2003US20030180817 Determining levels of a colon specific gene in the cells, or bodily fluids in a patient, comparing determined levels of CSG with levels of CSG in cells from normal human control, wherein a change in level of CSG indicates presence of cancer
09/25/2003US20030180810 For diagnosis, prevention, and treatment of reproductive disorders, Alzheimer's disease, cancer, immunological disorders, and diabetes
09/25/2003US20030180786 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
09/25/2003US20030180778 UDP-N-acetylglucosamine: galactose-beta1,3-N-acetylgalactosamine-alpha-R/ (GlcNAc to GalNAc) beta1,6-N-acetylglucosaminyltransferase, C2GnT3
09/25/2003US20030180752 Type 2 cytokine receptor and nucleic acids encoding same
09/25/2003US20030180739 Culturing a cell in the presence or absence of the compound, assaying the cell for expression or activity of gene(s), detecting the compound when expression of the genes is lower in the presence of the compound than in the absence
09/25/2003US20030180712 Host cells transfected with a recombinant expression vector containing nucleic acid control sequences operatively linked to an L-type Ca2+ channel beta 3 gene; host cell free of functional beta 3 subunit-containing L-type Ca2+ channels
1 ... 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 ... 1151